加载中
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
常规交易时段
US$5.065
−US$0.005 · -0.10%
盘中时间采用ET。市场数据可能有所延迟。
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
日内区间
当前US$5.065
52周区间
当前US$5.065
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
26
偏贵
情绪
42
多空交织
风险
54
风险偏高
动量
81
强势上行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
日内区间
当前US$5.065
52周区间
当前US$5.065
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | — | — | 172.1万 USD | 111.8万 USD |
| 毛利 | — | — | — | −172.1万 USD | −111.8万 USD |
| 研究与开发 | 2380.7万 USD | 2281.1万 USD | 1614.8万 USD | 2799万 USD | 3042.3万 USD |
| 销售、一般及管理费用 | 916万 USD | 521.8万 USD | 671.9万 USD | 1089.8万 USD | 1245.2万 USD |
| 营业费用 | 3296.7万 USD | 2802.9万 USD | 2286.7万 USD | 3716.7万 USD | 4202.7万 USD |
| 利息收入 | — | 44.2万 USD | 54.8万 USD | 26.7万 USD | 46.8万 USD |
| 利息支出 | 68.5万 USD | 152.5万 USD | 171.1万 USD | 133.9万 USD | — |
| 折旧和摊销 | 145.8万 USD | 162.2万 USD | 182.2万 USD | 172.1万 USD | 111.8万 USD |
| 营业利润 | −3296.7万 USD | −2802.9万 USD | −2286.7万 USD | −3888.8万 USD | −4314.5万 USD |
| 净利润 | −3416.9万 USD | −2902.2万 USD | −2386.5万 USD | −3952.5万 USD | −4071.3万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$12.50
上涨空间 146.79%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年9月21日 | 1:30 | — | — |
已生效 2023年9月21日
1:30
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
